Are There Therapeutic Strategies Targeting Chromatin Modifying Complexes?
Yes, targeting chromatin modifying complexes offers a promising avenue for cancer therapy. Several strategies are being pursued:
Histone Deacetylase Inhibitors (HDACis): These agents inhibit HDACs, leading to the reactivation of tumor suppressor genes. Examples include vorinostat and romidepsin, used in treating cutaneous T-cell lymphoma. EZH2 Inhibitors: Given the role of EZH2 in silencing tumor suppressor genes, inhibitors like tazemetostat are being developed for cancers with EZH2 mutations. Bromodomain and Extra-Terminal Domain (BET) Inhibitors: These inhibitors target proteins that recognize acetylated histones, thereby disrupting the expression of oncogenes. Compounds like JQ1 are in clinical trials for various malignancies.
